Selank Research Guide: Tuftsin Derivative & Anxiolytic Mechanism

Last Updated: April 14, 2026

Selank is a synthetic heptapeptide derived from the endogenous immunomodulator tuftsin, developed at the Russian Academy of Sciences Institute of Molecular Genetics. Its amino acid sequence—Thr-Lys-Pro-Arg-Pro-Gly-Pro—extends the native tuftsin tetrapeptide (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro stabilizing tail, a modification that dramatically increases resistance to enzymatic degradation and extends half-life in laboratory preparations. Preclinical research indicates that Selank exhibits a distinctive anxiolytic-like profile in animal models without the sedation, motor impairment, or dependence liability associated with benzodiazepine reference compounds. Published studies suggest the molecule engages GABAergic neurotransmission, modulates monoamine systems, and influences expression of brain-derived neurotrophic factor (BDNF), while retaining the immunomodulatory signature inherited from its tuftsin parent. This selank research guide summarizes the peptide’s structural biology, mechanism hypotheses, published preclinical literature, and standard laboratory handling protocols for investigators working with reference material.

What Is Selank and How Does It Relate to Tuftsin?

Selank is best understood as a stabilized research analog of tuftsin, a naturally occurring tetrapeptide fragment liberated from the Fc region of immunoglobulin G by enzymatic cleavage. Tuftsin itself is rapidly degraded by serum peptidases, which limits its utility as an experimental probe. Russian investigators addressed this by extending the C-terminus with the tripeptide Pro-Gly-Pro, yielding the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Preclinical research indicates the added proline-rich tail sterically protects the active tuftsin core from carboxypeptidase attack, substantially lengthening measurable presence in plasma compared with the parent tetrapeptide. This structural strategy—appending short stabilizing sequences to bioactive cores—appears in multiple Russian peptide research programs and is documented across published studies characterizing Selank’s pharmacokinetic profile in animal models.

What Does the N-Acetyl Modification Change?

N-Acetyl Selank (NA-Selank) adds an acetyl group to the N-terminal threonine residue. In laboratory characterization work, this modification confers additional resistance to aminopeptidases that would otherwise cleave the N-terminus, further extending the peptide’s effective lifetime in reconstituted solutions and biological matrices. Published studies suggest the pharmacological signature of NA-Selank closely parallels that of unmodified Selank in standard behavioral assays, with some investigators reporting modestly prolonged activity windows. For research protocols requiring extended stability during handling or where peptidase activity is anticipated, NA-Selank is commonly selected. Researchers comparing the two forms should note that while mechanism hypotheses remain similar, subtle differences in receptor-interaction kinetics and metabolite profiles have been described, and selection between variants should reflect the specific experimental question under investigation.

What Is the Anxiolytic-Without-Sedation Mechanism?

One of the most distinctive features reported in Selank preclinical research is an anxiolytic-like behavioral signature that does not co-occur with the sedation, ataxia, or memory impairment commonly observed with GABA-A positive allosteric modulators such as benzodiazepines. In elevated plus maze, open field, and conflict paradigms, animal models treated with Selank show reductions in anxiety-associated behaviors while retaining normal locomotor activity and learning performance. Preclinical research indicates this profile reflects modulation rather than direct agonism of inhibitory neurotransmission: Selank appears to influence GABAergic tone indirectly, in part through effects on enkephalin degradation and monoamine turnover. The absence of the classical sedation-dependence tradeoff has positioned Selank as a reference tool for investigators studying dissociable components of anxiety-related circuitry. See the nootropic peptides guide for broader context.

How Does Selank Modulate the GABA System?

Published studies suggest Selank engages GABAergic neurotransmission through an indirect pathway rather than binding the benzodiazepine site of the GABA-A receptor. Investigators have reported that Selank administration influences the expression of genes encoding GABA-A receptor subunits in hippocampal and cortical tissue, and alters enkephalinase activity, thereby shifting the balance of endogenous opioid peptides that themselves modulate GABA release. This upstream, network-level modulation is offered as one explanation for why Selank produces anxiolytic-like effects without the receptor-level saturation that drives sedation and tolerance in benzodiazepine research. Preclinical research indicates that tolerance, withdrawal, and cross-tolerance with benzodiazepines are absent or markedly reduced in standard Selank protocols, a pharmacological signature consistent with indirect modulation rather than direct allosteric potentiation of inhibitory receptors.

What Role Does BDNF Play in Selank Research?

Brain-derived neurotrophic factor (BDNF) is a secreted protein central to synaptic plasticity, hippocampal neurogenesis, and stress resilience. Preclinical research indicates Selank administration upregulates BDNF expression in hippocampal tissue, particularly under conditions of chronic stress exposure in rodent models. Published studies suggest this BDNF modulation may underlie the observed preservation of learning and memory performance in Selank-treated animals across maze and avoidance tasks, and provides a mechanistic link between the peptide’s anxiolytic-like signature and its reported cognitive-supportive profile. Investigators studying stress-induced reductions in BDNF have used Selank as a pharmacological probe to dissect the relationship between anxiety-associated behavior and neurotrophin signaling. For comparative context between the two major Russian-developed research peptides in this class, see Selank vs Semax.

What Immunomodulatory Properties Does Selank Retain?

Because Selank contains the full tuftsin tetrapeptide as its N-terminal core, it inherits measurable immunomodulatory activity in laboratory assays. Published studies report Selank influences cytokine expression profiles—including interleukin and interferon signatures—in peripheral blood mononuclear cell preparations and in rodent tissue following standard research protocols. Preclinical research indicates modulation of both innate and adaptive immune readouts, with reported effects on macrophage phagocytic activity inherited from tuftsin biology. This dual neurological-immunological signature distinguishes Selank from most anxiolytic reference compounds, which lack direct immune activity, and makes it a useful tool for investigators studying neuroimmune interactions, stress-associated immune suppression, and the intersection of anxiety-like behavior with inflammatory signaling in animal models. Research groups examining psychoneuroimmunology have cited this property when selecting Selank as an experimental probe.

What Does Intranasal Administration Reveal About Peptide Delivery?

A recurring feature of the Selank research literature is the use of intranasal administration in published animal protocols, a route that takes advantage of the olfactory and trigeminal pathways to deliver peptide material toward central nervous system targets while partially bypassing first-pass hepatic metabolism. Preclinical research indicates Selank retains measurable central activity following intranasal delivery in rodent studies, with behavioral and biochemical readouts comparable to parenteral routes in several published comparisons. Published studies suggest the Pro-Gly-Pro stabilization is particularly useful in this context, as intranasal mucosal peptidases would otherwise rapidly degrade the unprotected tuftsin core. Investigators designing Selank protocols should note that route-of-administration comparisons are a non-trivial dimension of experimental design, and that Russian research groups have extensively characterized intranasal delivery as a laboratory-relevant route for peptides in this class.

What Is the Russian Development History of Selank?

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, with principal characterization work conducted in collaboration with the V.V. Zakusov Institute of Pharmacology. The molecule emerged from a structured program investigating tuftsin analogs as candidate regulatory peptides and received approval in the Russian Federation for specific clinical indications following domestic regulatory review. Outside Russia, Selank remains a research-grade compound without marketing authorization in most jurisdictions, and laboratory use is the appropriate framing for investigators outside that regulatory context. Published studies from Russian groups—many available through PubMed indexing—form the bulk of the preclinical and early clinical literature, and references such as Zozulia et al. (PMID 11505544) and Medvedev et al. (PMID 20186610) provide foundational characterization of the peptide’s behavioral and molecular profile.

What Monoamine System Effects Have Been Reported?

Beyond GABAergic modulation, preclinical research indicates Selank influences monoaminergic neurotransmission in rodent models, with published studies reporting effects on serotonin and dopamine turnover in cortical and limbic tissue. Investigators using microdialysis and post-mortem neurochemical sampling have observed shifts in the ratios of monoamine metabolites to parent transmitters following Selank administration, consistent with modulation of synthesis, release, or reuptake processes. Published studies suggest these monoaminergic effects may contribute to the peptide’s cognitive-supportive profile and to the preservation of mood-associated behavioral readouts in stress models. This monoamine signature, combined with the GABAergic and neurotrophic effects described elsewhere in the literature, supports the conceptualization of Selank as a network-level modulator rather than a single-receptor agent, offering investigators a multi-mechanism research tool for studying the intersecting circuits underlying anxiety-like and cognitive-associated behaviors in animal models.

How Does Selank Engage Enkephalin Degradation Pathways?

One of the more specific mechanism hypotheses developed in the Russian Selank literature concerns inhibition of enkephalin-degrading enzymes, particularly enkephalinase activity, in brain tissue. Published studies suggest Selank administration reduces the rate of enkephalin breakdown, effectively prolonging the residence time of endogenous opioid peptides at their receptor targets. Because enkephalins themselves modulate GABAergic and monoaminergic tone, this upstream biochemical effect offers a unifying account of Selank’s diverse pharmacological signature without requiring direct agonism at any single receptor class. Preclinical research indicates the magnitude of enkephalinase inhibition correlates with behavioral readouts in anxiety and cognitive paradigms, supporting the hypothesis that endogenous opioid preservation is a central node in the Selank mechanism. This feature distinguishes the peptide from conventional anxiolytic reference compounds and shapes the experimental questions investigators design around it.

How Is Selank Reconstituted and Stored for Research?

Selank is supplied as a lyophilized white powder and should be stored at −20 °C in its sealed vial until reconstitution for laboratory use. Standard research protocols reconstitute lyophilized Selank with bacteriostatic water or sterile water depending on experimental requirements, introducing the diluent slowly along the vial wall to avoid mechanical stress to the peptide. Gentle swirling—not vigorous shaking—is used to dissolve the powder. Reconstituted solutions are typically stored at 2–8 °C and used within published stability windows, with freeze-thaw cycles minimized to preserve integrity. Concentration is calculated from the stated vial mass and diluent volume, and aliquoting into single-use fractions is a common strategy to avoid repeated vial entry. All handling is conducted under laboratory conditions appropriate for reference material and consistent with the stated research-only purpose of the compound.

Frequently Asked Questions

What is the difference between Selank and tuftsin?

Tuftsin is the endogenous tetrapeptide Thr-Lys-Pro-Arg, liberated from immunoglobulin G by enzymatic cleavage and active in macrophage biology. Selank is a synthetic heptapeptide that retains the full tuftsin sequence at its N-terminus and adds Pro-Gly-Pro at the C-terminus. Preclinical research indicates this extension dramatically increases resistance to peptidase degradation, extending measurable activity windows in laboratory preparations. The Selank molecule retains tuftsin’s immunomodulatory core while adding neurological activity—particularly anxiolytic-like and BDNF-modulatory effects—that are not consistently observed with tuftsin alone. Published studies suggest the Pro-Gly-Pro tail is not merely a stabilizer but contributes to the expanded pharmacological signature, and investigators comparing the two molecules in laboratory assays should select based on whether immunomodulatory, neurological, or combined readouts are the research focus.

How does Selank differ from benzodiazepines in research models?

In preclinical behavioral paradigms, Selank produces anxiolytic-like reductions in anxiety-associated behaviors comparable in magnitude to benzodiazepine reference compounds, but does so without the sedation, motor impairment, memory disruption, or tolerance development characteristic of GABA-A positive allosteric modulators. Published studies suggest this dissociation reflects Selank’s indirect modulation of GABAergic tone through effects on enkephalin metabolism and receptor subunit expression, rather than direct potentiation at the benzodiazepine binding site. Preclinical research indicates that cross-tolerance with benzodiazepines is not observed in standard protocols, and withdrawal signatures following discontinuation are absent or minimal. This profile makes Selank a useful probe for investigators studying dissociable components of anxiety circuitry in animal models. See PMID 11505544 for characterization.

What does BDNF modulation mean in practice for Selank research?

BDNF is a neurotrophin central to synaptic plasticity and stress resilience, and its expression is reduced in many rodent models of chronic stress. Preclinical research indicates Selank administration restores or elevates hippocampal BDNF expression in such models, a finding that investigators have linked to preserved performance on learning and memory tasks under conditions that would otherwise degrade cognitive readouts. Published studies suggest this BDNF signature provides a mechanistic bridge between Selank’s anxiolytic-like profile and its cognitive-supportive properties. Research groups studying the intersection of anxiety-like behavior and neuroplasticity have used Selank as a pharmacological tool to probe whether BDNF restoration is sufficient to reverse stress-induced behavioral deficits, with findings contributing to broader models of stress biology in animal research.

Is Selank the same as N-Acetyl Selank?

Selank and N-Acetyl Selank (NA-Selank) are structurally distinct. NA-Selank carries an acetyl group on the N-terminal threonine, which preclinical research indicates confers additional resistance to aminopeptidase cleavage and further extends the peptide’s effective lifetime in reconstituted solutions. Published studies suggest the pharmacological signatures of the two forms are broadly parallel in standard behavioral assays, though NA-Selank may exhibit modestly prolonged activity windows. Investigators selecting between the forms typically consider the stability requirements of the specific protocol, the anticipated peptidase activity of the research matrix, and whether fine comparative characterization between the two is itself a research goal. Both forms retain the tuftsin-derived immunomodulatory core and the Pro-Gly-Pro stabilizing tail that define the Selank family of analogs.

What published studies are foundational for Selank research?

The foundational preclinical characterization of Selank draws heavily from Russian research groups associated with the Institute of Molecular Genetics and the V.V. Zakusov Institute of Pharmacology. Key references include Zozulia et al. (PMID 11505544), which describes clinical and preclinical anxiolytic-like activity, and Medvedev et al. (PMID 20186610), which characterizes gene expression changes and BDNF-related signatures in animal models. Additional PubMed-indexed publications document the peptide’s immunomodulatory profile, its effects on enkephalin metabolism, and comparative studies with benzodiazepine reference compounds. Investigators beginning a literature review for Selank-based research protocols typically combine these Russian sources with later international publications to establish baseline mechanism hypotheses and appropriate experimental controls for laboratory work.

What reconstitution approach is standard for Selank laboratory use?

Standard research protocols reconstitute lyophilized Selank with bacteriostatic water or sterile water for laboratory use, with volume calculated from the stated vial mass and the desired working concentration. Diluent is introduced slowly along the vial wall to avoid mechanical disruption, and the vial is swirled gently—never shaken vigorously—until the powder fully dissolves. Reconstituted solutions are stored at 2–8 °C within published stability windows, and freeze-thaw cycles are minimized. For extended-use protocols, aliquoting into single-use fractions prior to freezing is common practice. The lyophilized vial itself is stored at −20 °C until reconstitution for research. All handling conforms to laboratory conditions appropriate for reference material, and investigators should maintain written reconstitution logs to support reproducibility across experimental runs.

Where can researchers source Selank reference material?

Peptideware supplies Selank 5mg as lyophilized reference material for laboratory and research purposes only. Each vial is characterized for identity and purity and is packaged under conditions consistent with published storage protocols. Investigators comparing Selank with its closest research analog may also find Selank vs Semax a useful reference, as both peptides emerged from Russian research programs and are frequently studied in parallel for their complementary nootropic-adjacent signatures. All products are intended for laboratory and research purposes only, are not for human or animal consumption, and are supplied with documentation appropriate for research-grade material.

---

Research Disclaimer: All products are intended for laboratory and research purposes only. Not for human or animal consumption. These statements have not been evaluated by the FDA. Content on this page summarizes published preclinical literature and is provided for educational reference to investigators working with research-grade material.